Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.

The Peter Attia Drive

View the Show Notes Page for This Episode
  Become a Member to Receive Exclusive Content
  Sign Up to Receive Peter's Weekly Newsletter
 In this "Ask Me Anything" (AMA) episode, Peter takes a deep dive into the liver and its central role in metabolic health. He explains why the liver can serve as a "canary in the coal mine" for metabolic dysfunction and explores how insulin resistance, visceral fat, alcohol consumption, genetics, and hormones contribute to liver disease, along with how increasing muscle mass can benefit liver health. Peter provides a framework for understanding the progression of liver disease, highlighting which stages are reversible and why early detection matters. He explains why normal liver enzymes can provide false reassurance, which labs he uses to assess liver health, and the tools available for detecting fibrosis and more advanced disease. Peter then breaks down the interventions that can meaningfully improve liver health once risk or disease is identified, ranging from diet and exercise to GLP-1–based therapies and other medications. Finally, he examines popular claims around liver "detoxification" and supplements, separating what is supported by evidence from what is unlikely to meaningfully improve liver health.
 If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #88 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
 We discuss:
  
Why the liver is the "canary in the coal mine" for metabolic dysfunction, and an overview of what the liver does [2:00];
 The relationship between the liver and blood sugar control [6:30];
 A framework for understanding how metabolic disease affects the liver [9:15];
 Chronic caloric surplus and insulin resistance as drivers of liver disease [11:00];
 Liver diseases that result from metabolic dysfunction and the difference between steatosis and fibrosis [15:15];
 How visceral fat affects liver health [20:00];
 The importance of lifestyle interventions for liver and metabolic health: resistance training, not drinking calories, and the impact of fructose [22:00];
 Why alcohol-associated liver disease is more common than we give it credit for [26:30];
 Genetic and hormonal risks for liver disease [31:45];
 Labs that objectively measure liver health and the FIB-4 score [35:30];
 FibroScan: non-invasive imaging of the liver [44:30];
 The resiliency of the liver: an organ that can heal itself [47:00];
 Fibrosis staging and its impact on mortality and cancer risk [49:15];
 Interventions for someone with MASLD: weight loss and GLP-1s [52:00];
 Other medications used to treat metabolic liver disease [57:00];
 The role of exercise in treating metabolic liver disease: caloric deficit and building muscle [59:45];
 The myth of liver detoxes and cleanses, and a few supplements that may benefit the liver [1:01:15];
 A practical summary: how to assess your risk and the levers that reverse the disease [1:08:00]; and
 More.
  
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#405 ‒ AMA #88: Metabolic liver health: how to assess risk, catch dysfunction early, and prevent or reverse liver disease

View the Show Notes Page for This Episode
  Become a Member to Receive Exclusive Content
  Sign Up to Receive Peter's Weekly Newsletter
 In this episode, Peter sits down with Dr. Linus Abrams, a psychiatrist with nearly 35 years of clinical experience specializing in mood disorders and psychopharmacology, to explore how our understanding of mental health is evolving beyond the traditional neurotransmitter model. After decades in practice, Linus began questioning many of the assumptions underlying modern psychiatry, leading him to investigate how hormones, metabolism, inflammation, circadian biology, and the endocrine system shape mood and cognition. Together, Peter and Linus examine why psychiatric care should aim not only to reduce symptoms but also to restore the full human experience. They discuss how psychiatric medications work, where they fall short, and why distinguishing bipolar disorder from unipolar depression is essential for effective treatment. The conversation also explores the growing mental health burden of social isolationn associated with digital devices and social media, along with the biological factors—nutrition, exercise, sleep, and chronic stress—that influence resilience and distress tolerance. Linus explains the powerful roles of estrogen, progesterone, testosterone, and thyroid hormone in regulating mood and cognition across the lifespan. Finally, Peter and Linus review the promise and limitations of ketamine and psychedelic therapies, and why the future of psychiatry may lie in integrating neuroscience, endocrinology, and whole-body physiology to better understand, diagnose, and treat mental illness.
 We discuss:
  
Linus's passion for understanding his patients and going beyond traditional psychiatry [2:45];
 A short primer on the different classes of drugs used in psychiatry [12:45];
 Evaluation of a patient with bipolar disorder [26:00];
 An evolutionary perspective on depression [33:30];
 Changes in the modern world triggering mental health problems [41:00];
 An evolutionary perspective on insomnia [48:15];
 Peter's window analogy to understand distress tolerance and irritability [49:45];
 The impact of foundational biological factors on psychiatry: nutrition, exercise, sleep, and endocrinology [52:30];
 The effect of estradiol on neurotransmitters in the brain [58:15];
 Options for increasing testosterone in men, and why clomiphene is inferior to exogenous testosterone [1:11:00];
 The rapid drop in progesterone is linked to both premenstrual dysphoric disorder (PMDD) and postpartum depression [1:14:30];
 Treatment of postpartum depression [1:18:00];
 Hypothyroidism presenting as depression: how Linus makes the diagnosis and what he uses for treatment [1:26:00];
 The link between hyperarousal and chronically elevated cortisol [1:39:30];
 A case where the menopause transition uncovers bipolar disorder [1:44:15];
 Ketamine as a tool to treat recalcitrant depression, and concerns about its recreational use [1:49:15];
 Case study: an Alzheimer's patient who improved after psilocybin, and why Linus is cautious about drawing conclusions from it [1:55:15];
 Peter's experience with psychedelics, and the myth that estrogen is bad for men [2:00:30];
 The therapeutic potential of psychedelics in psychiatry [2:11:00]; and
 More.
  
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.

View the Show Notes Page for This Episode
  Become a Member to Receive Exclusive Content
  Sign Up to Receive Peter's Weekly Newsletter
 In this episode, Peter returns to the topic of peptides, offering a clear and accessible guide to a field surrounded by both genuine scientific promise and widespread misinformation. Peptides are increasingly marketed for everything from injury recovery and muscle growth to longevity and improved appearance, often with claims that extend far beyond the available evidence. Rather than promoting or dismissing peptides as a category, Peter presents a practical framework for evaluating any peptide: what it is, how it is supposed to work, and where the science is strong, weak, or simply absent. He then applies this framework to a specific example before examining the risks of gray-market products, concerns about sourcing and quality, and where the field may be headed—ultimately helping listeners distinguish legitimate therapies from hope that has been packaged and sold without sufficient evidence.
 We discuss:
  
What peptides are and why they must be evaluated individually [3:15];
 A five-question framework for evaluating peptides and other drugs [5:30];
 A three-tier system for classifying the scientific evidence behind peptides [10:00];
 Evaluating BPC-157: unclear mechanisms, absent human evidence, and unknown risks [14:00];
 Why BPC-157's expanding claims do not indicate a broad mechanism [20:45];
 CJC-1295: biological activity versus meaningful clinical benefit [23:30];
 Why testimonials about peptide benefits cannot establish the effectiveness of peptides [27:30];
 The placebo effect, and the importance of controlled trials for evaluating peptides [31:00];
 What FDA approval provides when evaluating peptide safety and effectiveness [34:45];
 Why prescriptions from doctors, compounding pharmacies, and third-party testing do not validate unapproved peptides [38:30];
 Approved peptides sold on the gray market: why evidence for an approved peptide does not automatically extend to gray-market versions [40:45];
 Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented [43:00];
 The promise of peptide science, and the risks of the gray-market wellness industry [46:30];
 Why peptide claims must be falsifiable and why evidence should precede widespread use rather than be expected to catch up later [49:00]; and
 More.
  
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#403 ‒ Peptides: separating scientific promise from marketing hype

View the Show Notes Page for This Episode
  Become a Member to Receive Exclusive Content
  Sign Up to Receive Peter's Weekly Newsletter
 Jim Otvos is a biophysical chemist who pioneered the use of nuclear magnetic resonance (NMR) spectroscopy to measure lipoprotein particles and developed the first FDA-cleared method for directly quantifying LDL particle number (LDL-P), a technology that has since expanded to provide broader insights into metabolic health, inflammation, insulin resistance, and mortality risk. In this episode, Jim recounts the unlikely story of transforming a flawed cancer test into a new way of measuring lipoproteins, explains what standard cholesterol tests can miss and why LDL-P and apoB can inform treatment decisions beyond LDL cholesterol alone, and dispels the misconception that large, "fluffy" LDL particles are benign. He also explores how NMR can reveal insulin resistance before blood sugar rises, GlycA as a marker of chronic low-grade inflammation, and the metabolic vulnerability index (MVX) as a potential measure of frailty, resilience, and mortality risk across the lifespan. Finally, Jim explains why NMR diagnostics remain underused despite the wealth of information they can extract from a single blood test.
 We discuss:
  
How investigating a flawed 1986 cancer test led to the development of NMR (nuclear magnetic resonance) lipoprotein testing [3:30];
 How standard lipid panels measure cholesterol and triglycerides, and why LDL cholesterol is estimated rather than directly measured [15:15];
 How NMR spectroscopy measures lipoprotein particle size and concentration [20:30];
 Why LDL particle number matters more than particle size, and why large, "fluffy" LDL is not benign [28:45];
 Discordance between LDL cholesterol and LDL particle number: which measure better reflects cardiovascular risk? [36:30];
 How metabolic syndrome and lipid-lowering treatment contribute to the discordance between LDL-C and LDL-P, and the value of particle number for managing risk [45:30];
 Using the NMR-derived LP-IR score to detect insulin resistance and predict type 2 diabetes before glucose rises [51:15];
 The development, commercialization, and uncertain future of the Vantera NMR Analyzer and NMR-based diagnostics [1:04:45];
 The analytical efficiency of NMR testing and the data-driven development of the Metabolic
 Vulnerability Index (MVX) [1:16:00];
 GlycA as an NMR-derived marker of systemic inflammation: its discovery, biological basis, and advantages over hs-CRP [1:25:45];
 Developing the Metabolic Vulnerability Index (MVX): biomarkers of inflammation, malnutrition, muscle wasting, and mortality risk [1:34:00];
 What MVX can tell us about longevity and mortality [1:44:15];
 How MVX may reveal metabolic frailty and predict premature mortality decades in advance in young, healthy adults [1:50:30];
 Potential applications of MVX for predicting treatment response, surgical resilience, and clinical trial outcomes, and the barriers to broader use [2:00:00];
 ApoB versus LDL-P: their clinical similarities, the additional information provided by NMR, and barriers to broader adoption [2:07:30];
 Interpreting the effects of the CETP inhibitor, obicetrapib, on LDL-P, apoB, and small HDL particles [2:13:00];
 The future of NMR diagnostics and MVX: translating scientific potential into broader clinical use [2:20:45]; and
 More.
  
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.

View the Show Notes Page for This Episode
  Become a Member to Receive Exclusive Content
  Sign Up to Receive Peter's Weekly Newsletter
 In this episode of The Drive, Peter explores how seemingly obscure basic science discoveries have laid the foundation for some of the most important medical breakthroughs of the past half century. Rather than focusing on the clinical applications of modern therapies, he traces the fascinating stories behind the scientists, experiments, and unexpected discoveries that ultimately led to transformative drug classes, revealing how groundbreaking advances often emerge from research with no obvious clinical goal. Through these historical case studies, Peter provides a new perspective on the unpredictable path of medical innovation and makes the case for why investing in basic scientific research remains essential for driving the next generation of life-changing therapies.
 We discuss:
  
The discovery of green fluorescent protein (GFP): how curiosity about glowing jellyfish transformed modern biology [2:30];
 Why basic research and nature's biological innovations are the foundation of medical progress [10:45];
 The discovery of statins: how fungi provided the blueprint for cholesterol-lowering drugs [15:15];
 From snake venom to ACE inhibitors: the discovery of a cornerstone therapy for cardiovascular disease [21:00];
 From Yellowstone hot springs to PCR: how Thermus aquaticus transformed modern biology and medicine [28:00];
 The discovery of CRISPR: from salt flats to gene editing and genetic medicine [37:15];
 The discovery of GLP-1 receptor agonists: from Gila monster venom to a new era in metabolic medicine [47:30];
 Why curiosity-driven basic research is essential for the future of medical innovation [54:15]; and
 More.
  
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#401 ‒ How curiosity transforms medicine: extraordinary discoveries that changed modern healthcare

View the Show Notes Page for This Episode
  Become a Member to Receive Exclusive Content
  Sign Up to Receive Peter's Weekly Newsletter
 In this "Ask Me Anything" (AMA) episode, Peter explores the evidence behind environmental pollution and its impact on long-term health, separating well-supported risks from less substantiated claims while providing a practical framework for deciding which exposures deserve attention. He explains what environmental pollution encompasses, where it fits within the broader hierarchy of longevity interventions, and why studying its health effects is uniquely challenging. Peter examines the evidence linking air pollution to disease and shares actionable strategies for improving indoor and outdoor air quality. He also discusses how noise and light pollution can influence sleep, cardiovascular health, and overall well-being, offering practical ways to reduce their effects in daily life. Finally, Peter takes an evidence-based look at electromagnetic fields (EMFs) and 5G technology, evaluating the current science and whether concerns about these exposures are supported by the available data.
 If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #87 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
 We discuss:
  
Defining environmental pollution and its role in longevity [1:45];
 Why the topic of environmental pollution is both polarizing and difficult to study [6:00];
 Where environmental exposures fit within the hierarchy of health priorities, and a framework for evaluating which environmental risks are worth addressing [13:15];
 Understanding air pollution: the major pollutants and why PM2.5 is a key marker of health risk [16:00];
 Indoor air pollution: why indoor air quality often matters most for reducing personal air pollution exposure [21:45];
 How air pollution is measured and how the Air Quality Index (AQI) translates pollution data into practical guidance [25:00];
 The health effects of air pollution: evidence linking exposure to respiratory and cardiovascular disease [27:00];
 How air pollution causes disease: biological mechanisms linking pollution to respiratory and cardiovascular health [29:15];
 Who is most susceptible to the health effects of air pollution? [31:45];
 Understanding air pollution thresholds and the differences between WHO and EPA air quality guidelines [34:15];
 Comparing acute air pollution events with chronic exposure and cumulative health risk [36:15];
 Best strategies for mitigating air pollution exposure [38:00];
 Noise pollution: effects on hearing, sleep, and cardiovascular health [44:30];
 Measuring noise exposure and understanding the thresholds for hearing loss and chronic health effects [48:00];
 Practical strategies to reduce noise exposure and protect your hearing [54:15];
 Light pollution: defining light pollution and the importance of timing for circadian health [58:15];
 The health effects of artificial light at night and the evidence behind blue light and blue light-blocking glasses [1:00:00];
 Practical strategies for optimizing light exposure to support circadian rhythms and sleep [1:04:00];
 Concerns about EMF and 5G exposure: understanding electromagnetic fields and the distinction between ionizing and non-ionizing radiation [1:06:30];
 Evaluating the evidence linking radiofrequency electromagnetic fields to cancer risk [1:10:15];
 Evaluating the evidence for electromagnetic hypersensitivity and EMF-related symptoms [1:14:00];
 Practical recommendations for managing everyday EMF and 5G exposure and avoiding unnecessary interventions [1:15:30];
 Prioritizing environmental exposures based on their impact on health and longevity [1:18:00];
 The highest-ROI strategies for reducing environmental pollution exposure and protecting long-term health [1:19:30]; and
 More.
  
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#400 ‒ AMA #87: Environmental pollution and longevity: air pollution, noise, light, EMFs, and practical strategies to mitigate health risks

View the Show Notes Page for This Episode
  Become a Member to Receive Exclusive Content
  Sign Up to Receive Peter's Weekly Newsletter
 Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer's disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer's disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care.
 We discuss:
  
Gayatri's training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45];
 How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15];
 The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30];
 Gayatri's comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45];
 Why forgetting names is usually normal and when word-finding problems become concerning [29:00];
 Why women are at higher risk for Alzheimer's disease and how menopause influences cognition [33:45];
 The promise and limitations of blood-based biomarkers for diagnosing Alzheimer's disease [40:15];
 When preclinical Alzheimer's screening is appropriate and how to interpret positive biomarker results [45:00];
 Case study: early Alzheimer's prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15];
 Anti-amyloid therapies: balancing clinical benefit with ARIA risk using slow titration [51:45];
 The aducanumab controversy, why it was discontinued, and why Gayatri would still choose it [1:00:00];
 How anti-amyloid therapies cause ARIA, strategies for detecting and managing these complications, and how future therapies may improve safety and accessibility [1:03:30];
 Two patient examples of exceptional responses to anti-amyloid therapy [1:12:30];
 A multimodal approach to Alzheimer's treatment: combination therapy, MRI-guided TMS, GLP-1 receptor agonists, and more [1:15:00];
 Vascular dementia, Lewy body dementia, and the overlap with Alzheimer's disease [1:21:00];
 Lewy body dementia and Parkinson's disease: distinguishing two alpha-synuclein disorders [1:26:45];
 Risk factors for Lewy body dementia and what remains unknown [1:36:15];
 Treating menopause-related cognitive impairment: hormone therapy, brain rehabilitation, and balancing breast cancer risk [1:38:45];
 How biomarkers changed Gayatri's perspective on the potential for Alzheimer's patients to improve [1:47:15];
 The future of Alzheimer's care: AI, precision medicine, and personalized treatment [1:49:30]; and
 More.
  
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

View the Show Notes Page for This Episode
  Become a Member to Receive Exclusive Content
  Sign Up to Receive Peter's Weekly Newsletter
 In this "Ask Me Anything" (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably.
 We discuss:
  
Peter's humorous experience talking nutrition with a second grader [3:00];
 Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:30];
 Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:45];
 The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [11:00];
 Grip strength as a simple yet powerful predictor of all-cause mortality [17:15];
 Is muscle strength causal or just a marker of health? [20:30];
 Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [23:00];
 How muscle mass and strength enhance healthspan by supporting metabolic health, inflammation control, recovery from illness, mobility, and fall prevention [24:15];
 How muscle mass and strength decline with age, and why it's essential to act early to slow decline and preserve function later in life [31:00];
 The foundational principles of building muscle strength and size through resistance training [36:00];
 How to apply "progressive overload" for long-term strength and muscle gains [40:00];
 The difference between concentric and eccentric muscle contractions and how each impacts strength, hypertrophy, and injury prevention [45:15];
 The differences between muscle fiber types, and how aging disproportionately affects fast-twitch fibers responsible for power [50:45];
 How to effectively train for power [52:30];
 Training intensity: the benefits and safety of using the "reps in reserve" method [53:30];
 How to balance compound and isolation exercises in a workout routine, and why compound lifts are foundational [56:15];
 Can bodyweight exercises build muscle as effectively as weight training? [58:15];
 How women can effectively build strength and muscle: key considerations [59:45];
 Effective methods for tracking progress in strength [1:01:45];
 Effective methods for tracking progress in muscle mass, and how to interpret results from a DEXA scan [1:05:00];
 How to balance workout frequency with recovery for optimal results [1:07:15];
 How to recognize signs of overtraining and when to consider taking rest days [1:10:45];
 Avoiding injury: how beginners or returning lifters can start resistance training safely [1:15:45];
 Protein: recommended intake, quality sources, timing of consumption, and more [1:18:00];
 How fasting and calorie restriction affect muscle mass and what can be done to minimize muscle loss [1:24:45];
 Key nutritional factors beyond protein that support muscle growth: hydration, creatine, and recovery [1:28:15];
 The impact of hormones, sleep, stress, and consistency on muscle building and recovery [1:29:15];
 How to structure an effective workout routine for a younger person who is new to resistance training [1:32:00];
 How to modify beginner resistance training programs for older individuals to prioritize safety and gradual progress [1:36:00];
 Should beginners start with machines or free weights when resistance training? [1:37:00];
 How experienced lifters should modify their training to support healthspan and performance in later life [1:38:30]; and
 More.
  
Connect With Peter on Twitter, Instagram, Facebook and YouTube

Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)

View the Show Notes Page for This Episode
  Become a Member to Receive Exclusive Content
  Sign Up to Receive Peter's Weekly Newsletter
 In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass.
 If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
 We discuss:
  
The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45];
 Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45];
 How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15];
 Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30];
 Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15];
 The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00];
 Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45];
 Why lean mass measurements are an imperfect proxy for muscle health and function [21:45];
 The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00];
 Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00];
 Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00];
 Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45];
 Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00];
 Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00];
 Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45];
 Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15];
 Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00];
 The risks of using gray-market retatrutide before FDA approval [52:15];
 Key takeaways [54:30]; and
 More.
  
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

View the Show Notes Page for This Episode
  Become a Member to Receive Exclusive Content
  Sign Up to Receive Peter's Weekly Newsletter
  View our full terms of use
 Renato Tomioka is a leading expert in reproductive medicine and gynecologic surgery whose unique skills allow him to diagnose and treat some of the most impactful yet frequently overlooked conditions affecting women's health. In this episode, Renato explores endometriosis and adenomyosis, explaining what these conditions are, why they often go undiagnosed for years despite affecting millions of women worldwide, and how advances in MRI and specialized ultrasound are transforming diagnosis beyond traditional surgical laparoscopy. He discusses the decision-making process behind hormonal therapy versus surgery, how treatment strategies change when fertility preservation is a priority, and where IVF fits into the care pathway for women with endometriosis, adenomyosis, or age-related fertility decline. Renato also examines the profound effects of female age on egg quality and quantity, including the accelerating rise in chromosomal abnormalities after age 35, highlights common mistakes in both surgical and fertility management, and shares promising developments on the horizon for treating these conditions and preserving fertility.
 Follow Dr. Tomioka's work: Instagram: @dr.renatotomioka; Website: Renato Tomioka, M.D., Ph.D.
 We discuss:
  
0:00:00 - Intro
 0:00:11 - Endometriosis: definition, prevalence, infertility risk, and theories of disease development
 0:09:03 - The biology of endometriosis: estrogen dependence, progesterone resistance, and tumor-like growth mechanisms
 0:13:25 - Adenomyosis explained: how it differs from endometriosis, why it develops, and its impact on reproductive health
 0:18:52 - Recognizing endometriosis and adenomyosis: the "6 Ds" of endometriosis and key differences in clinical presentation
 0:22:09 - Uterine fibroids: classification, symptoms, and the importance of fibroid location for bleeding and fertility
 0:24:09 - Understanding endometriosis pain: lesion-driven pain, nerve involvement, central sensitization, and the importance of early treatment
 0:28:26 - Endometriosis in young women: rising prevalence, delayed diagnosis, and barriers to care
 0:33:11 - Modern diagnosis of endometriosis: specialized ultrasound, MRI, and the decline of diagnostic laparoscopy
 0:45:52 - Clinical case example #1: Managing endometriosis in a young woman seeking pain relief while preserving future fertility
 0:54:10 - Clinical case example #2: Comparing treatment strategies for symptom control versus fertility
 1:01:24 - Endometriosis and fertility: the roles of age, embryo quality, IVF, and surgery
 1:11:50 - Clinical case example #3: Managing adenomyosis after failed IVF transfers to improve implantation and pregnancy outcomes
 1:20:51 - The funding gap in endometriosis research: disease burden, economic impact, and growing awareness
 1:22:01 - Clinical case example #4: Surgical decision-making in endometriosis—balancing pain relief, fertility preservation, and common treatment pitfalls
 1:27:43 - Common misconceptions about fertility: maternal age, embryo aneuploidy, the inefficiency of human reproduction, and the limits of IVF
 1:34:23 - Elective egg freezing: timing, success rates, the fertility funnel, and the tradeoffs of fertility preservation
 1:45:49 - Emerging fertility technologies: mitochondrial replacement, ovarian tissue preservation, stem-cell-derived eggs, and current limitations
 1:55:10 - The future of endometriosis treatment: new guidelines, biologic therapies, and unanswered questions about IVF
 1:58:30 - Why earlier diagnosis matters: reducing years of suffering from endometriosis and adenomyosis
  
Connect With Peter on Twitter, Instagram, Facebook and YouTube